ADAM17 and cancer: Importantly, A17pro is cross‐species reactive (i.e., mouse and human) and thus provides an advantage over human‐specific ADAM17 antibodies which cannot be evaluated for efficacy in genetically engineered mouse models of cancer (Richards et al, 2012).